# Genomic surveillance of SARS-CoV-2 in Belgium

Report of the National Reference Laboratory (UZ Leuven & KU Leuven)

Situation update - 28 of January 2021 (5<sup>th</sup> report for 2021)

#### **Executive summary**

Genomic surveillance in Belgium is based on whole genome sequencing (WGS) of a selection of representative samples, complemented with targeted active surveillance initiatives aiming to early detect and precisely monitor the presence of variants of concern (VOCs). Currently, 3.368 sequences of samples collected in Belgium since the start of the epidemic are available on GISAID in open access.

Since the 1st of December 2020, a total of 1.977 sequences have been produced by the sequencing platforms participating to the federal genomic surveillance initiative. 601 501Y.V1 and 91 501Y.V2 VOCs have been identified (increasing trend; numbers are an under-estimation of the current situation). As 87% of "S dropout" PCR results are now confirmed by sequencing, it is not anymore mandatory that these strains are systematically sequenced to confirm the presence of 501Y.V1. The proportion of presumptive 501Y.V1 remains estimated between 15% and 25% of all positive strains.

Belgium has recently experienced multiple introductions of variants of VOCs, particularly since the last days of 2020. The consolidated genomic and epidemiological data are consistent with a rapidly increasing number of events of local transmission, including in schools and nursery homes. Circulation of VOCs is steadily increasing in all age groups.

### **Content of this document**

- International context
- Belgian genomic surveillance
- Monitoring of variants of concern (VOCs)
- Strengthened surveillance of VOCs
- Relative importance of VOCs compared to other circulating strains in Belgium

Authors (National Reference Laboratory – UZ Leuven and KU Leuven): Piet Maes, Lize Cuypers, Guy Baele, Els Keyaerts, Elke Wollants, Marc Van Ranst, Emmanuel André

### Provided data for to this report:

Barney Potter (KUL), Samuel Hong (KUL), Simon Dellicour (ULB), Bruno Verhasselt (UGent), Herman Goossens (UA), Keith Durkin (ULiège), Cécile Meex (CHU Liège), Jonathan Degosserie (CHU Mont-Godinne)

# 1. International context

Since the end of the year, 3 variants of concern (VOCs) have arisen independently of one another in the United Kingdom (501Y.V1), South Africa (501Y.V2) and Brazil (501Y.V3). These variants harbour a number of mutations and deletions associated with higher infectiousness and immune escape. All 3 variants are spreading internationally, with 501Y.V1 and 501Y.V2 having been detected in Belgium.

# 2. Belgian genomic surveillance

The National Reference Centre hosted at UZ Leuven – KU Leuven has put in place genomic surveillance at the national level since the first introduction of the virus in February 2020. Along the way, other university centres have contributed to this surveillance effort through complementary initiatives, and the federal government has recently supported a scale-up of this network, built upon the federal platform laboratories. During the last week, a few clinical laboratories have independently started submitting a limited number of sequences on GISAID. To date, 3.368 sequences originating from Belgian laboratories were uploaded on GISAID and are available in open access. The map hereunder represents the current availability of sequences per province in Belgium.

**Baseline Surveillance.** A representative sampling of the positive cases in Belgium organised with the collaboration of a sentinel network of laboratories, allows to follow over the time the trends in the genetic diversity of circulating strains of SARS-CoV-2. 24 pre-selected labs were contacted by the National Reference lab and agreed to refer 5% of their positive samples for the baseline surveillance system. The first shipments of samples have been organised and the sentinel network should be fully set up in the coming weeks. The selection of participating labs was made to ensure an optimal geographical coverage and a diversity of clinical severity patterns (university hospitals, regional hospitals, GPs and community-based testing centres). The aim is to cover at all times a minimum of 2% of all positive cases in Belgium, with the possibility to increase this coverage if asked or required for public health reasons.

Active surveillance aims to promptly identify the introduction of emergence of (possible) variants of concern (VOCs). This surveillance is available for all clinical laboratories and does not systematically require WGS testing. Currently, active surveillance in Belgium focuses on:

- > Systematic screening of VOCs among returning travellers
- Systematic screening of VOCs among atypical PCR or antigen diagnostic test results (including "S dropouts")
- Genetic characterization of a subset of strains in the situation of outbreaks
- Genetic characterization among patients experiencing re-infection or infection after vaccination
- Genetic characterization among patients presenting a higher risk of chronic infection and mutant selection (e.g. immunocompromised, antiviral therapy)

## 3. Monitoring of variants of concern (VOCs)

Since the 1<sup>st</sup> of December, 1.977 sequences have been produced by the participating sequencing laboratories. During the week of 18/1/2021, 7 out of 39 WGS analysis performed in the context of baseline surveillance were confirmed 501Y.V1 (20%).

The graph below highlights the increasing number of VOCs detected by WGS per week (based on sampling date) since the first VOC was detected in Belgium. Of note, due to the important number of samples, all platform bis laboratories do not systematically confirm anymore by WGS the 501Y.V1 VOC when del69 and 501Y are observed, nor confirm 501Y.V2 when 501Y is present. The figure below therefore underestimates the actual detection of VOCs.



## 4. Relative importance of VOCs compared to other circulating strains in Belgium

Across the 8 laboratories composing the federal testing platform (over 484.000 PCR tests performed since 1/12/2020), the proportion of "S dropouts" among positive SARS-CoV-2 PCR is between 15% and 25% (last 8 days).



In parallel, the proportion of WGS-confirmed 501Y.V1 among "S dropouts" has increased over the last 4 weeks, and was 87% during the last 2 weeks (441 confirmed among 507 sequenced for "S dropout"). Therefore, although non-501Y.V1 strains harbouring del69 (causing the S dropout) still circulate in Belgium, the amount and the evolution of "S dropout" PCR results can currently be considered as a very good marker of the evolution of the 501Y.V1 in Belgium.

We received the distribution by age and week for "S dropouts" and "non S dropouts" positive PCR results from 7 out of 8 platform bis laboratories for the last 4 weeks. This data supports the introduction of 501Y.V1 in the first week of the year (returning travellers), mainly detected in the adult population. More recently, a higher number of these strains have been detected in younger and older groups, possibly resulting of a combination of factors: higher transmissibility including in nursing homes and the educational sector, and an intensified testing strategy offered in these groups.

	# S-gene dropouts						# non S-gene dropouts				pouts		
Week		0 - 19	20 - 39	40 - 59	60 - 79	80 - 99		0 - 19	20 - 39	40 - 59	60 - 79	80 - 99	
	Namur	years	years	years	years	years		years	years	years	years	years	
28-12 - 3/1		. 0	1	. 0	0	. 0		29	74	49	22	1	
4/1 - 10/1		1	6		1	4		47	167	105	42	6	
4/1-10/1		1	0		-	-		47	107	105	92	0	
11/1-1//1		U	3	U	4	ð		55	97	8/	35	1	
18/1 - 24/1		3	4	4	4	15		48	69	91	45	8	
			# S-	gene drop	outs				# non	S-gene dro	pouts		
Week	Leuven	0-19	20 - 39	40 - 59	60 - 79	80 - 99		0 - 19	20 - 39	40 - 59	60 - 79	80 - 99	
		vears	vears	vears	vears	vears		vears	vears	vears	vears	vears	
28-12 - 3/1		1	2	2	1	0		31	60	48	29	q	
20 22 3/2		-	-	-		0	-			-10	20	20	
4/1-10/1		3	1	U	1	0		40	11	60	30	20	
11/1 - 17/1		1	10	3	5	2		53	98	62	26	18	
18/1 - 24/1		28	9	11	7	7		35	92	56	23	40	
Week	Liège		# S-	gene drop	outs		# non S-gene dropouts						
	-	0 - 19	20.39	40 - 59	60 - 79	80 - 99		0 - 19	20.39	40.59	60 - 79	80 - 99	
		Veare	Voare	VOOR	voare	voare		VOAR	VOOR	VOOT	Voare	voare	
20.42.2/:		7 Cars	1 5013	7 0013	10013	10015		10013	7 5013	years	y cars	10015	
28-12 - 3/1		0	0	0	0	0		2	5	9	6	3	
4/1-10/1	1	0	0	0	0	0		9	28	40	26	47	
11/1 - 17/1		0	3	0	0	0	11	11	20	38	15	28	
18/1-24/1		2	2	1	0	0		12	12	7	12	24	
			-				-						
Week	III B	1	# C_	gene drop	outs	-			# non	S-gene dre	nouts	-	
CCR	010	0 10	π 3- 20 20	40 E0	60 70	80 00		0 10	# 11011	AO EO	60 70	80 00	
		u - 19	20 - 39	40 - 59	60 - 79	80 - 99		u – 19	20 - 39	40 - 59	60 – 79	80 - 99	
	I	years	years	years	years	years		years	years	years	years	years	
28-12 - 3/1	L	1											
4/1-10/1													
11/1 - 17/1		28	58	56	14	12		53	195	143	42	16	
18/1 - 24/1		19	50	57	18	28		53	139	108	32	30	
10/1-24/1		15	50	37	10	20	_	33	135	100	32	50	
		-		<u> </u>									
Week	Mons		# S-	gene drop	outs				# non	S-gene dro	pouts		
		0 - 19	20 - 39	40 - 59	60 – 79	80 - 99		0 – 19	20 - 39	40 - 59	60 – 79	80 - 99	
		years	years	years	years	years		years	years	years	years	years	
28-12 - 3/1		0	1	3	1	0		49	154	124	62	16	
4/1 - 10/1		0	2	2	1	0		46	189	172	85	22	
11/1 - 17/1		0	2	-	2	1		80	170	120	01	24	
11/1-1//1		0					-	00	1/5	130	51	24	
18/1-24/1		2	5	4	2	1		101	141	1/6	78	34	
Week	UCL		# S-	gene dropouts					# non S-gene dr		opouts		
		0-19	20 - 39	40 - 59	60 - 79	80 - 99		0 - 19	20 - 39	40 - 59	60 - 79	80 - 99	
		years	years	years	years	years		years	years	years	years	years	
28-12 - 3/1		1	1	3	1	. 0		52	141	113	27	6	
4/1 - 10/1	1			0		0					-	c	
11/1 17/1		0	0	0	0	U		90	201	175	55		
11/1-17/1		0	23		-			80	281	175	55		
18/1-24/1	1		20	,	6	0		80 96	281 396	175 239	55 61	14	
		14	30	20	6 5	0		80 96 69	281 396 174	175 239 128	55 61 52	14 31	
		14	30	20	5	0		80 96 69	281 396 174	175 239 128	55 61 52	14 31	
Week	Antwerp	14	30 # S-	20 gene drop	6 5 outs	0		80 96 69	281 396 174 # non	175 239 128 S-gene dro	55 61 52 pouts	14 31	
Week	Antwerp	14 0-19	30 # S- 20 - 39	20 gene drop	6 5 outs 60 - 79	0 0 80 - 99		80 96 69 0 - 19	281 396 174 # non 20 - 39	175 239 128 S-gene dro 40 - 59	55 61 52 pouts 60 – 79	14 31 80 - 99	
Week	Antwerp	14 0 - 19 years	30 # S- 20 - 39 years	20 gene drop 40 - 59 years	6 5 outs 60 – 79 years	0 0 80 - 99 years		80 96 69 0 - 19 vears	281 396 174 # non 20 - 39 years	175 239 128 S-gene dro 40 - 59 years	55 61 52 pouts 60 – 79 years	14 31 80 - 99 years	
Week	Antwerp	14 0 – 19 years	30 # S- 20 - 39 years	20 gene dropo 40 - 59 years	6 5 outs 60 – 79 years	0 0 80 - 99 years		80 96 69 0 - 19 years	281 396 174 # non 20 - 39 years	175 239 128 S-gene dro 40 - 59 years	55 61 52 pouts 60 - 79 years	14 31 80 - 99 years	
Week 28-12 - 3/1	Antwerp	14 0 – 19 years	30 # S- 20 - 39 years 4	gene dropo 40 - 59 years 4	6 5 0uts 60 - 79 years 0	0 0 80 - 99 years 1		80 96 69 0 - 19 years 58	281 396 174 # non 20 - 39 years 127	175 239 128 S-gene dro 40 - 59 years 122	55 61 52 pouts 60 - 79 years 54	14 31 80 - 99 years 66	
Week 28-12 - 3/1 4/1 - 10/1	Antwerp	14 0 - 19 years 5	30 # S- 20 - 39 years 4 10	20 gene dropp 40 - 59 years 4	6 5 0uts 60 - 79 years 0 1	0 0 80 - 99 years 1 0		80 96 69 0 - 19 years 58 73	281 396 174 # non 20 - 39 years 127 177	175 239 128 S-gene dro 40 - 59 years 122 186	55 61 52 pouts 60 - 79 years 54 59	14 31 80 - 99 years 66 61	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1	Antwerp	14 0 - 19 years 5 9 11	30 # S- 20 - 39 years 4 10 26	20 gene dropp 40 - 59 years 4 5 22	6 5 0uts 60 - 79 years 0 1 1	0 0 80 - 99 years 1 0 0		80 96 69 0 - 19 years 58 73 85	281 396 174 # non 20 - 39 years 127 177 171	175 239 128 S-gene dro 40 - 59 years 122 186 142	55 61 52 60 – 79 years 54 59 65	14 31 80 – 99 years 66 61 67	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp	14 0 – 19 years 5 9 111 63	30 # S- 20 - 39 years 4 10 26 32	20 gene drop 40 - 59 years 4 5 22 35	6 5 0uts 60 - 79 years 0 1 1 5	0 0 80 - 99 years 1 0 0		80 96 69 0 - 19 years 58 73 85 137	281 396 174 # non 20 - 39 years 127 177 171 143	175 239 128 S-gene dro 40 - 59 years 122 186 142 124	55 61 52 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp	14 0 - 19 years 5 9 111 63	30 # S- 20 - 39 years 4 10 26 32	20 gene dropp 40 - 59 years 4 5 22 35	6 5 5 60 - 79 years 0 1 1 5	0 0 80 - 99 years 1 0 0		80 96 69 0 - 19 years 58 73 85 137	281 396 174 # non 20 - 39 years 127 177 171 143	175 239 128 S-gene dro 40 - 59 years 122 186 142 124	55 61 52 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp	14 0 - 19 years 5 9 11 63	30 # S- 20 - 39 years 4 10 26 32	20 gene dropp 40 - 59 years 4 5 22 35	6 5 5 60 - 79 years 0 1 1 5	0 0 80 - 99 years 1 0 0		80 96 69 0 - 19 years 58 73 85 137	281 396 174 # non 20 - 39 years 127 177 171 143	175 239 128 S-gene dro 40 - 59 years 122 186 142 124	55 61 52 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp	14 0 - 19 years 5 9 11 63	30 # S- 20 - 39 years 4 10 26 32	20 gene dropp 40 - 59 years 4 5 22 35	6 5 0uts 60 - 79 years 0 1 1 5	0 0 80 - 99 years 1 0 0 1		80 96 69 0 - 19 years 58 73 85 137	281 396 174 # non 20 - 39 years 127 177 171 143	175 239 128 S-gene drc 40 - 59 years 122 186 142 124	55 61 52 900ts 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp	14 0 - 19 years 5 9 11 63	20 - 39 years 4 10 26 32	20 gene dropp 40 - 59 years 4 5 22 35	6 5 00uts 60 - 79 years 0 1 1 5	0 0 80 - 99 years 1 0 0		80 96 69 0 - 19 years 58 73 85 137	281 396 174 # non 20 - 39 years 127 177 171 143	175 239 128 S-gene drc 40 - 59 years 122 186 142 124	55 61 52 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp	14 0 - 19 years 5 9 9 111 63	30 # S- 20 - 39 years 4 10 26 32	20 gene dropp 40 - 59 years 4 5 22 35	6 5 0uts 60 - 79 years 0 1 1 1 5	0 0 80 - 99 years 1 0 0 1		80 96 69 0 - 19 years 58 73 855 137	281 396 174 20 - 39 years 127 177 171 143	175 239 128 S-gene drc 40 - 59 years 122 186 142 124	55 61 52 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp	14 0 - 19 years 5 9 11 63	# S- 20 - 39 years 4 10 26 32	20 gene drop 40 - 59 years 4 5 22 35	6 5 0 - 79 years 0 1 1 5	0 0 80 – 99 years 1 0 0 1		80 96 69 0 - 19 years 58 73 85 137	281 396 174 # non 20 - 39 years 127 177 171 143	175 239 128 S-gene drc 40 - 59 years 122 186 142 124	55 61 52 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp	14 0 - 19 years 9 111 63	20 - 39 years 4 100 26 32	20 gene drop 40 - 59 years 4 5 22 35	6 5 0 - 79 years 0 1 1 5	0 0 90 - 99 years 1 0 0 0		80 96 69 0 - 19 years 58 73 85 137	281 396 174 # non 20 - 39 years 127 177 171 143	175 239 128 S-gene drc 40 - 59 years 122 186 142 124	55 61 52 60 - 79 years 54 59 65 5 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp	14 0 - 19 years 9 11 63	20 - 39 years 4 10 26 32	20 gene drop 40 - 59 years 4 5 222 35	6 5 00uts 60 - 79 years 0 1 1 5	0 0 80 - 99 years 1 0 0 1		80 96 69 0 - 19 years 58 73 85 137	281 396 174 # non 20 - 39 years 127 177 171 143	175 239 128 S-gene drc 40 - 59 years 122 186 142 124	55 61 52 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1 Week	Antwerp	14 0 - 19 years 5 9 11 63	# S- 20 - 39 years 4 10 26 32 # S-	gene drop 40 - 59 years 4 5 22 35	6 5 00-79 years 0 1 1 5	80 – 99 years 1 0 1		80 96 69 0 - 19 years 58 73 85 137	281 396 174 # non 20 - 39 years 127 177 171 143	175 239 128 S-gene drc 40 - 59 years 122 1866 142 124	55 61 52 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1 Week	Antwerp	14 0-19 years 5 9 11 63	# S- 20 - 39 years 4 100 26 32 # S- 20 - 39	20 gene drop: 40 - 59 years 4 5 22 35 22 35 22 35 4 0 4 0 - 59 years 4 - 59 years 4 - 59 years 4 - 59 years - 4 - 59 years - 59 - 59 years - 59 years - 59 - 59	6 5 5 60 - 79 years 0 1 1 5 5 5 0 0 2 5 60 - 79	80 - 99 years 1 0 1 80 - 99		80 96 69 0 - 19 years 58 73 85 5 137	281 396 174 # non 20 - 39 years 127 177 171 143 # non 20 - 39	175 239 128 S-gene drc 40 - 59 years 122 186 142 124 5-gene drc 40 - 59	55 61 52 60 - 79 years 54 59 65 41	14 31 80 - 99 years 66 61 67 40 80 - 99	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1 Week	Antwerp	14 0-19 years 5 9 111 63 0-19 years	# S- 20 - 39 years 4 10 26 32 32 # S- 20 - 39 years	gene drop 40 - 59 years 4 5 22 35 9 9 9 9 9 40 - 59 9 9 40 - 59	6 5 Duts 60 - 79 years 0 1 1 5 0 60 - 79 years 0 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0	80 - 99 years 0 0 1 80 - 99 years		80 96 69 0 - 19 years 58 73 85 137 0 - 19 years	281 396 174 # non 20 - 39 years 127 177 171 143 43 44 20 - 39 years	175 239 128 S-gene drc 40 - 59 years 122 186 142 124 S-gene drc 40 - 59 years	55 61 52 60 - 79 years 59 65 41 9 65 41 60 - 79 years	14 31 80 - 99 years 66 61 67 40 80 - 99 years	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1 Week Week	Antwerp Total	14 0 - 19 years 5 9 111 63 63 0 - 19 years	# 5- 300 20 - 39 years 4 10 26 32 32 # 5- 20 - 39 years	20 gene dropp 40 - 59 years 4 5 22 35 22 35 22 35 22 35 22 35 22 35 22 35 22 35 22 35 22 35 22 23 22 20 20 20 20 20 20 20 20 20 20 20 20	6 5 60 - 79 years 0 1 1 1 5 5 5 0 0 7 9 9 0 1 1 5 5 0 0 7 9 9 0 1 1 1 1 5 5	0 80 - 99 years 1 0 0 1 80 - 99 years		80 96 69 years 58 73 85 137 0 - 19 years 0 - 19 years	281 396 174 # non 20 - 39 years 127 177 171 143 # non 20 - 39 years 20 - 39	175 239 128 S-gene drc 40 - 59 years 122 186 142 124 5-gene drc 40 - 59 years	55 61 52 900tts 60 - 79 99 65 41 90 65 41 900tts 60 - 79 9ears 60 - 79 9ears	14 31 80 - 99 years 66 61 67 40 80 - 99 years	
Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1 Week 28-12 - 3/1 (1, - 10/1)	Antwerp 	14 0-19 years 5 9 9 111 63 0-19 years 7 7	# S- 300 # 20 - 39 years 4 100 26 32 # S- 20 - 39 years 9 9	gene dropr 40 - 59 years 4 35 22 35 9 4 0 - 59 years 12	6 5 5 60 - 79 years 1 1 1 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	0 80 - 99 years 1 0 0 1 80 - 99 years		80 96 69 97 58 73 85 85 137 137 0 - 19 years 221	281 396 174 # non 20 - 39 years 127 177 177 143 43 43 20 - 39 years 561	175 239 128 S-gene drc 40 - 59 years 122 186 142 124 5-gene drc 40 - 59 years 465	55 61 52 60 - 79 years 54 59 65 65 41 41 60 - 79 years 200	14 31 80 - 99 years 66 61 61 67 40 80 - 99 years 80 - 99	
Week 28-12 - 3/1 14/1 - 10/1 11/1 - 17/1 18/1 - 24/1 Week 28-12 - 3/1 4/1 - 10/1	Antwerp 	14 0 - 19 years 9 111 63 0 - 19 years 7 13	# S- 300 # S- 20 - 39 years 4 10 26 32 # S- 20 - 39 years 9 19	20 gene dropp years 4 5 22 35 35 35 9 9 9 9 9 9 9 9 9 9 9 9 9 12 12 12	6 5 60 - 79 years 0 1 1 1 5 5 60 - 79 years 3 4	0 80 - 99 years 1 0 0 1 80 - 99 years 1 4		80 96 69 97 98 73 85 137 0 - 19 99 98 221 295	281 396 174 # non 20 - 39 years 127 177 171 143 # non 20 - 39 years 561 919	175 239 128 S-gene drc 40 - 59 years 122 1866 142 124 5-gene drc 40 - 59 years 465 738	55 61 52 90045 60 - 79 965 41 60 - 79 90045 60 - 79 90045 200 297	14 31 80 - 99 years 66 61 67 40 80 - 99 years 101 162	
Week 28-12 - 3/1 11/1 - 10/1 11/1 - 17/1 18/1 - 24/1 Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1	Antwerp	14 0 - 19 years 9 9 111 63 0 - 19 years 7 133 40	300 # 5- 20 - 39 years 4 10 266 32 32 # 5- 20 - 39 years 9 199 126	20 gene dropp 40 - 59 years 222 35 35 gene dropp 40 - 59 years 12 90	6 5 0 - 79 years 0 1 1 5 5 60 - 79 years 3 4 32	80 - 99 years 1 0 0 1 80 - 99 years 1 4 23		80 96 69 0 - 19 years 58 73 85 5 137 0 - 19 years 221 295 433	281 396 174 # non 20 - 39 years 127 171 143 443 443 20 - 39 years 561 919 91	175 239 128 40 - 59 years 122 186 142 124 5-gene drc 40 - 59 years 465 7388 849	55 61 52 60 - 79 years 54 55 41 41 60 - 79 years 200 297 335	14 31 80 - 99 years 66 61 67 40 80 - 99 years 101 162 168	
Week 28-12 - 3/1 11/1 - 10/1 11/1 - 17/1 18/1 - 24/1 Week 28-12 - 3/1 4/1 - 10/1 11/1 - 17/1 18/1 - 24/1	Antwerp Total	14 0 - 19 years 9 111 63 0 - 19 years 7 13 40 131	300 # 5- 20 - 39 years 4 100 26 32 # 5- 20 - 39 years 9 19 126 122	20 gene dropp 440 - 59 years 222 35 222 35 44 - 59 years 12 40 - 59 years 12 12 900 9132	6 5 60 - 79 years 0 1 1 5 60 - 79 years 60 - 79 years 3 4 32 41	80 - 99 years 80 - 99 years 1 80 - 99 years 1 4 23 52		80 96 69 0 - 19 years 73 85 137 0 - 19 years 221 295 433 455	281 396 174 # non 20 - 39 years 127 177 171 143 44 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	175 239 128 S-gene drc 40 - 59 years 122 1866 142 124 5-gene drc 40 - 59 years 465 738 849 690	55 61 52 60 - 79 years 54 59 65 41 60 - 79 years 200 297 335 283	14 31 80 - 99 years 66 61 67 40 80 - 99 years 101 162 162 168 207	

Since 11/1/2021, we observe among all age groups a higher increase rate from one week to the other in the "S gene dropout" group compared to the "non S gene dropout" group. This is consistent with the observations previously made of a higher infectiousness of the 501Y.V1 variant.

% increase	Total	# S-gene dropouts						# non S-gene dropouts					
from one week to the other		0 – 19 years	20 - 39 years	40 - 59 years	60 – 79 years	80 – 99 years		0 – 19 years	20 - 39 years	40 - 59 years	60 – 79 years	80 – 99 years	
28-12 - 3/1													
4/1 - 10/1		186%	211%	100%	133%	400%		133%	164%	159%	149%	160%	
11/1 - 17/1		308%	663%	750%	800%	575%		147%	126%	115%	113%	104%	
18/1 - 24/1		328%	105%	147%	128%	226%		105%	67%	81%	84%	123%	

## 5. Strengthened surveillance of VOCs

- Technical validation of rapid targeted multi-target PCRs aiming to detect and presumptively characterize VOCs is ongoing in two laboratories
- A meeting with all clinical laboratories (>100 participants) has been organised on 28/1/2021 to explain the genomic surveillance plan and the current epidemiological situation
- A meeting with all provincial governors has been organised on 28/1/2021 to explain the current epidemiological situation and the implications
- Several media communications have been made to explain the current situation (FR and NL media)
- Discussions with RIZIV-INAMI are ongoing to consolidate the genomic surveillance initiative